首页 | 本学科首页   官方微博 | 高级检索  
     


A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
Authors:Roman Hajek  Ludek Pour  Muhit Ozcan  Jesus Martin Sánchez  Ramon García Sanz  Achilles Anagnostopoulos  Albert Oriol  Nicola Cascavilla  Andreas Terjung  Yihua Lee  Eva M. Briso  Edyta Dobkowska  Bernhard Hauns  Ivan Špička
Affiliation:1. University Hospital of Ostrava, Ostrava-Poruba-Poruba, Czech Republic;2. University Hospital Brno, Brno, Czech Republic;3. Ankara University School of Medicine, Ankara, Turkey;4. Hospital Universitario Virgen del Rocio, Sevilla, Spain;5. University Hospital of Salamanca, Salamanca, Spain;6. General Hospital of Thessaloniki “G. Papanikolaou,", Thessaloniki, Greece;7. Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain;8. IRCCS “Casa Sollievo della Sofferenza” Hospital, San Giovanni Rotondo, Italy;9. Pharmacyclics Switzerland GmbH, an AbbVie Company, Schaffhausen, Switzerland;10. Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA;11. 1st Department of Medicine - Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic
Abstract:
Keywords:bortezomib  dexamethasone  ibrutinib  multiple myeloma
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号